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Nicotine withdrawal is associated with cognitive deficits including attention, working 
memory, and episodic memory impairments. These cognitive deficits are a hallmark of 
nicotine abstinence which could be targeted in order to prevent smoking relapse. The 
underlying mechanisms, however, are poorly understood. In this study, memory 
impairment was observed in mice 4 days after the precipitation of nicotine withdrawal by 
the nicotinic antagonist mecamylamine. The presence of cognitive deficits correlated with 
microglial activation in the hippocampus and the prefrontal cortex. Moreover, an 
increased expression of neuroinflammatory markers including IL1β, TNFα and IFNγ was 
found in both memory-related brain regions. Notably, flow cytometric analysis also 
revealed an enhancement of TNFα and IFNγ plasmatic levels at the same time point 
during nicotine withdrawal. Impaired neurogenesis, as shown by reduction in the 
expression of the endogenous cell proliferation marker Ki67 and the early neuron marker 
doublecortin, was also associated with nicotine abstinence. Treatment with the non-
psychoactive cannabinoid cannabidiol abolished memory impairment of nicotine 
withdrawal and microglia reactivity, reduced the expression of IL1β and IFNγ in the 
hippocampus and the prefrontal cortex, respectively, and normalized Ki67 levels. The 
nonsteroidal anti-inflammatory drug indomethacin also prevented cognitive deficits and 
microglial reactivity during withdrawal. These data underline the usefulness of anti-
inflammatory agents to improve cognitive performance during early nicotine abstinence.  
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Tobacco consumption remains a leading cause of preventable disease and mortality 
causing, worldwide, more than 5 million deaths per year (Gowing et al, 2015). Most of 
smokers who try to quit relapse within the first week of abstinence, pointing to early 
withdrawal as a critical window in maintaining tobacco abstinence (Ashare and Schmidt, 
2014). Cessation from tobacco smoking leads to a withdrawal syndrome characterized by 
physical, affective and cognitive symptoms (Hall et al, 2015). Increasing attention has 
focused on cognitive impairments that emerge during early smoking abstinence which 
include alterations in attention, working memory and episodic memory (Wesnes et al, 
2013; Hall et al, 2015). Indeed, these cognitive deficits seem to be involved in smoking 
relapse (Patterson et al, 2010), and therefore enhancement of memory performance during 
abstinence may represent a novel target for nicotine dependence pharmacotherapies 
(Ashare et al, 2014; Ashare and Schmidt, 2014). Available rodent models reveal the 
presence of cognitive deficits during nicotine withdrawal (Hall et al, 2015) providing an 
excellent preclinical model to investigate new pharmacological agents with cognitive-
enhancing properties.  
Many disorders of the central nervous system (CNS) characterized by cognitive deficits 
may have an inflammatory component underneath (Blank and Prinz, 2013). In these 
pathological conditions, microglia activation, release of inflammatory cytokines and 
altered neurogenesis seem to influence cognitive performance (Kohman and Rhodes, 
2013). A potential link between smoking and inflammation has been widely established 
although these studies have mainly focused on the relationship between inflammatory 
markers and increased cardiovascular risk (Wannamethee et al, 2005; Lo Sasso et al, 
2016). However, the potential role of neuroinflammation in the cognitive deficits 
associated with early nicotine withdrawal remains to be elucidated.    
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Cannabidiol is a non-psychoactive cannabinoid from Cannabis sativa plant with known 
anti-inflammatory and neuroprotective properties (Fernández-Ruiz et al, 2013; Burstein, 
2015). Some studies using inflammation-based models reveal that cannabidiol 
administration can attenuate cognitive deficits including spatial learning and memory, 
recognition memory and associative learning impairments (Osborne et al, 2017). 
Interestingly, a potential usefulness of cannabidiol in tobacco addiction has been shown 
in recent clinical studies (Morgan et al, 2013; Hindocha et al, 2018a). Thus, cannabidiol 
administration reduces cigarette consumption in tobacco smokers (Morgan et al, 2013), 
and the salience and pleasantness of cigarette cues after overnight abstinence in dependent 
smokers (Hindocha et al, 2018a).       
In this study, we investigated the role of neuroinflammation and neurogenesis in the 
cognitive deficits of the nicotine withdrawal syndrome in male mice. We also evaluated 
the effects of cannabidiol, a promising anti-inflammatory compound, in memory 
performance during nicotine withdrawal and the potential mechanisms involved in this 
response. The effects of cannabidiol were compared to those produced by the classical 




2. Materials and Methods  
2.1. Animals 
All experiments were performed in 8-weeks old male C57BL/6J mice (Charles River). 
Mice were housed 4 per cage in a temperature (21 ± 1°C) and humidity (55 ± 10%) 
controlled room with a 12-h/12-h light/dark cycle (light between 08:00 to 20:00). All 
experiments took place during the light phase. Food and water were available ad libitum. 
Animal procedures were conducted in accordance with the guidelines of the European 
Communities Directive 2010/63/EU regulating animal research and approved by the local 
ethical committee (CEEA-IMAS-UPF), and the statement of compliance with standards 
for use of laboratory animals for foreign institutions nr. A5388-01 approved by the 
National Institutes of Health. The observer was blind to treatment in all the experiments. 
 
2.2. Drugs 
(-)-Nicotine hydrogen tartrate salt [(−)-1-methyl-2-(3-pyridyl)pyrrolidine (+)-bitartrate 
salt] (Glentham Life Sciences) was dissolved in physiological saline (0.9% NaCl) and 
administered at the dose of 25mg/kg/day by using subcutaneously (sc) implanted osmotic 
minipumps. Nicotine dose was calculated as (-)-nicotine hydrogen tartrate salt. 
Mecamylamine hydrochloride (2mg/kg, Sigma) was dissolved in physiological saline and 
administered sc. Cannabidiol (3, 10 and 30mg/kg, THC Pharm) and indomethacin 
(2mg/kg, Sigma) were diluted in 5% ethanol, 5% cremophor, 90% saline and 
administered intraperitoneally (ip). The effects of cannabidiol and indomethacin in the 
cognitive deficits of nicotine withdrawal were performed in different groups of mice. 
Animals were randomly assigned to the different drug conditions. All drugs were 
administered in a volume of 10ml per kg of body weight. Doses of nicotine, 
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mecamylamine, cannabidiol and indomethacin were based on previous studies (Ren et al, 
2009; Ho et al, 2015; Saravia et al, 2017; Stern et al, 2017).  
 
2.3. Nicotine treatment and withdrawal  
Nicotine dependence was induced by using Alzet osmotic minipumps (Model 2002, 
Alzet®, Cupertino, USA). Minipumps previously filled with saline or nicotine solution 
were implanted sc in mice under brief isofluorane anesthesia. Minipumps delivered a 
constant sc flow in rate of 0.5μl/hour during 14 days. Nicotine concentration was adjusted 
to compensate differences in mice body weight. Thus, the average weighed mice received 
a dose of 25mg/kg/day of nicotine tartrate (equivalent to 8.12mg/kg/day nicotine free 
base). Fourteen days after minipump implantation, nicotine withdrawal syndrome was 
precipitated by the administration of the nicotinic receptor antagonist mecamylamine 
(2mg/kg). Systemic administration of mecamylamine in nicotine-treated rodents is a well-
established model to study the neurobiological mechanisms involved in the different 
aspects that characterize the nicotine withdrawal syndrome (Muldoon et al, 2015; Qi et 
al, 2015; Parikh et al, 2016; Saravia et al, 2017), typically observed in abstinent smokers.   
 
2.4. Evaluation of somatic signs of nicotine withdrawal 
Somatic signs of nicotine withdrawal were evaluated immediately after mecamylamine 
injection during a period of 25 minutes, as previously reported (Berrendero et al, 2005). 
The number of wet dog shakes, front paw tremors, and scratches were recorded. Body 
tremor, ptosis, teeth chattering, genital licks, and piloerection were scored 1 for 
appearance or 0 for nonappearance within each 5-minute period. The locomotor activity 
over 5-minute periods was rated 0, 1, or 2 (0 for inactivity, 1 for low activity, and 2 for 
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normal activity). A global withdrawal score was calculated for each animal by giving 
each individual sign a relative weight: 0.5 for each episode of wet dog shake, front paw 
tremor, and scratching; 1 for the presence of ptosis, genital licks, body tremor, 
piloerection, and teeth chattering, for each observation period of 5 minutes. The relative 
weight of locomotor activity for each 5 minute period was 0 for normal activity, 0.5 for 
low activity, and 1 for inactivity (Berrendero et al, 2005).  
 
2.5. Object-recognition task  
In rodents, the object-recognition task is widely used to evaluate hippocampal-dependent 
learning, which is a trait of episodic memory (Ennaceur, 2010). We used this test to 
evaluate the presence of cognitive deficits during nicotine withdrawal, as previously 
reported (Borkar et al, 2017; Saravia et al, 2017). The novel object recognition test has 
been widely used to reveal memory impairment induced by different drugs of abuse 
including methamphetamine (Tran et al, 2018) and morphine (Morisot and Contarino, 
2016). The object-recognition test was performed in a V-maze made of black plexiglas 
with 2 corridors (30 cm long x 4.5 cm wide) set in V with a 90º angle and 15 cm high 
walls. On the 13th day after minipump implantation mice were habituated to the V-maze 
for 9 minutes. On the 14th day, mice were placed back in the maze for 9 minutes where 
2 identical objects were presented (training phase). Nicotine withdrawal was precipitated 
20 minutes after training by the administration of mecamylamine (2mg/kg), allowing to 
test the influence of nicotine withdrawal on memory consolidation. To evaluate memory 
24 hours after precipitation of withdrawal mice were placed in the V-maze on the 15th 
day for 9 minutes where one of the familiar objects used the day before was replaced by 
a novel object. Cannabidiol (10mg/kg) or vehicle were injected immediately after 
training, 20 minutes before mecamylamine injection in saline and nicotine-treated mice.   
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To evaluate memory 4 days after nicotine withdrawal, we used a similar methodology as 
the previously described except that mice had another training session on day 17 and the 
test was performed on day 18. Cannabidiol (3, 10 and 30mg/kg), indomethacin (2mg/kg), 
or the corresponding vehicles were injected once daily during four days (immediately 
after training on day 14, and on days 15, 16 and 17) in saline and nicotine-treated mice.  
During the test session, the total time that mice spent exploring each of the 2 objects 
(novel, Tn and familiar, Tf) was recorded. Object exploration was defined as the 
orientation of the nose to the object at a distance of ≤ 2 cm. A discrimination index was 
calculated as the difference between the times spent exploring either the novel or familiar 
object divided by the total time exploring the 2 objects D.I. = [Tn–Tf]/[Tn+Tf]. A higher 
discrimination index is considered to reflect greater memory retention for the familiar 
object. 
 
2.6. Immunofluorescence studies 
Four days after the precipitation of nicotine withdrawal, immediately after the object 
recognition test, saline and nicotine-treated mice were deeply anesthetized and 
intracardically perfused with 4% paraformaldehyde (PFA) solution. Brains were removed 
from skull and post-fixed in PFA for 24 hours at 4ºC. Then, brains were transferred to a 
solution of 30% sucrose in PB 0.1M and kept at 4ºC. Coronal sections of 30µm were 
obtained using a microtome and slices were stored in a 5% sucrose PB 0.1M solution. 
Brain areas coordinates relative to bregma were:  hippocampus (from -1.34 to -2.46 mm), 
prefrontal cortex (PFC) (from 1.98 to 1.70 mm), and dorsal striatum (from 0.86 to 0.38 
mm). Free floating slices were rinsed in PB 0.1M and after blocked in a solution 
containing 3% donkey serum and 0.3% Triton X-100 in PB 0.1M (DS-T-PB) during 2 
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hours at room temperature. Slices were incubated overnight in DS-T-PB at 4ºC with the 
primary antibody to Iba1 (1:500, rabbit, Wako), Ki67 (1:150, mouse, Abcam) or 
doublecortin (DCX) (1:200, goat, Santa Cruz Biotechnology). Next day, after 3 rinses 
with PB 0.1M, slices were incubated with their corresponding secondary antibody 
AlexaFluor-555 donkey anti-rabbit (1:500), AlexaFluor-488 donkey anti-mouse (1:500) 
or AlexaFluor-555 donkey anti-goat (1:500) from Life Technologies at room temperature 
for 2 hours in DS-T-PB. Then, slices were rinsed three times and mounted with 
Fluoromount-G™ onto glass slides coated with gelatin. 
 
2.7. Microglia morphological analysis 
Images from Iba1 stained cells were acquired using a confocal microscope (Leica TCS 
Sp5 STED) with an oil immersion lens 40x/1.3 and 1x zoom. A 30μm z-stack image with 
0.29μm depth intervals was obtained from every slice. Microglial cell architecture was 
examined using ImageJ software on flattened images. The perimeter of microglial soma 
was measured using the tool “Freehand line” and the option “Analyze and Measure”. Four 
images per brain area of a minimum of 4 animals per group were analyzed. 
 
2.8. Ki67 and doublecortin analysis 
Images from Ki67 and DCX labeling were obtained using a confocal microscope (Leica 
TCS Sp5 STED) with 10x/0.40 dry lens and 2x zoom. A 30μm z-stack image with 1.01 
μm depth intervals was obtained from every slice. All DCX images were acquired using 
the same laser gain and intensity. For Ki67 and DCX analysis z-stack images were 
flattened. Quantification of Ki67+ cells in the subgranular zone (SGZ) of the 
hippocampus was performed using the ImageJ tool “Multi-point” to mark and count 
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Ki67+ cells. SGZ area was the result of its length (measured using the “Segmented line” 
tool) x its wide (25μm). Density of Ki67+ cells was calculated as Ki67+ cells divided per 
SGZ area. Four images per brain area of a minimum of 4 animals per group were 
analyzed. DCX fluorescence intensity in the granular cell layer was measured using the 
ImageJ software. Slices for all experimental groups were processed simultaneously to 
avoid difference in staining. Additionally, microscope settings were tailored to obtain 
images without pixel saturation but maintaining the same gain intensity. Images were 
adjusted to a dark background and processed to a binary image. Using the “Segmented 
line” tool and “Analyze and Measure” option, we measured the integrated density of the 
granular cell layer. Integrated density represents the mean grey value x area. To reduce 
bias, the integrated density of a single slice was the mean of 3 different measurements. 
Relative DCX integrated density (as evaluated in Walker et al, 2007) is represented as a 
percentage of the control treatment. Four images per brain area of a minimum of 4 animals 
per group were analyzed. 
 
2.9. RNA extraction and reverse transcription 
Hippocampus and PFC tissues from control and nicotine-treated mice were extracted 4 
days after the precipitation of nicotine withdrawal and were immediately frozen and store 
at -80ºC. Isolation of total RNA was performed using an RNeasy Mini kit (QIAGEN) for 
hippocampus or the RiboPure™ RNA Purification Kit (Invitrogen) for PFC according to 
the manufacturer’s instructions. The quality of the total RNA was assessed by the 
spectrophotometric ratio of A260/A280 (1.9:2.1). Total RNA concentration was 
measured using a NanoDrop spectrophotometer (Thermo Fisher Scientific). Reverse 
transcription was performed with 0.3 μg of total RNA from each animal to produce cDNA 
in a 20μl reaction with 200 units of SuperScript III Reverse Transcriptase (Invitrogen) 
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and 500-ng oligo(dT) primers. Reverse transcriptase reactions were carried out at 25°C 
for 10 minutes, then at 42°C for 50 minutes, and at 70°C for 15 minutes. The resulting 
cDNAs from these reactions were stored at –20°C until use. 
 
2.10. Quantitative real-time PCR analysis 
Quantitative real-time PCR was carried out with a QuantStudio 12K Flex Real-Time PCR 
System (Applied Biosystems) using the SYBR Green PCR Master Mix (Applied 
Biosystems) according to the manufacturer’s protocol. All the samples were tested in 
triplicate, and the relative expression values were normalized to the expression value of 
GAPDH. The primers sequences used for IL1β, TNFα, IL10, IL6, IFNγ, COX1, COX2, 
BDNF and GAPDH are indicated in Supplemental Table S1. Samples were analyzed by 
the ΔΔCt method. ΔΔCt values were calculated as the ΔCt of each test sample (different 
pharmacological treatments) minus the mean ΔCt of the calibrator samples (saline-
vehicle group) for all the genes analyzed. The fold change was calculated using the 
equation 2(–ΔΔCt). 
 
2.11. Flow cytometric analysis 
Blood samples from saline and nicotine-treated mice were collected at 2 different time 
points: 4 and 8 days after the precipitation of nicotine withdrawal. All blood samples were 
collected into 1.5mL EDTA coated tubes containing 10ul of EDTA 0.5M. The samples 
were centrifuged at 3000 rpm for 15 min at 4°C and plasma was stored at −80°C. A 
multiplex bead-array assay was used to quantify cytokines (TNFα, IL10 and IFNγ) in 
plasma samples. These cytokines were chosen according to mouse antibodies availability 
and previous analysis of mRNA expression in hippocampus and PFC. 
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The method is based on the binding of cytokines to different capture beads. This capture 
beads exhibit defined fluorescence properties and they can be analyzed by standard 
fluorescence cytometry. The MACSplex Cytokine kit (Miltenyi Biotec) for mouse was 
used according to the manufacturer’s instructions to detect TNFα (MACSPlex TNFα 
Reagents Kit, mouse), IL10 (MACSPlex IL10 Reagents Kit, mouse) and IFNγ 
(MACSPlex IFNγ Reagents Kit, mouse) (Miltenyi Biotec). Plasma samples were thawed 
at room temperature and then placed on wet ice for duration of analysis. One vial of mixed 
standards was freshly reconstituted in 0.2 mL of assay diluent, and then was serial diluted. 
The concentrations of standards for each cytokine were 0, 3.2, 16, 80, 400, 2000, and 
10000 pg/mL. Three types of cytokine capture beads were freshly mixed in equal amounts 
(2μL of each cytokine capture beads per test) and fill up to 20μL of assay diluent. To 
perform the assay, 20μL of the mixed beads were incubated with 50μL of standards or 
plasma samples in a MACSPlex filter plate at room temperature for 2 hours. After 3 
washes, the beads were resuspended in 100μL of the mix (2μL of each cytokine detection 
reagent per test) and were incubated at room temperature for 1 hour. The measurement 
was performed by means of the MACSQuant 10 Analyzer (Miltenyi Biotec) and the data 
were automatically analyzed using the respective tool from the MACSQuantifiy software. 
 
2.12. Data analysis  
Data were analyzed using unpaired Student t test, or two-way ANOVA with nicotine and 
cannabidiol or indomethacin treatments as between factors of variation. Subsequent post 
hoc analysis (Newman-Keuls test) was used when required. The Pearson correlation 
coefficient was used to analyze the relationship between discrimination index values and 
microglial perimeter soma. All data were analyzed using Statistica (StatSoft) software. 
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3.1. Microglial activation and impaired neurogenesis correlate with the cognitive 
deficits during nicotine withdrawal 
The object-recognition task was used to assess the presence of cognitive deficits during 
nicotine withdrawal. Nicotine abstinence was induced by mecamylamine administration 
(2mg/kg) 20 minutes after the first training session, and memory was evaluated 4 days 
after withdrawal precipitation (Fig. 1A). Memory impairment and structural plasticity 
changes during nicotine withdrawal were previously reported at this time point (Saravia 
et al, 2017). Mecamylamine does not affect memory by itself at this dose (Saravia et al, 
2017). Nicotine-treated mice exhibited a lower discrimination index compared with 
controls (p<0.01) (Fig. 1B), as previously reported (Saravia et al, 2017). Memory 
performance differences were not due to locomotor activity alterations since both 
experimental groups showed similar times of exploration (Fig. 1C).  
Cognitive deficits have been associated with inflammatory responses in many CNS 
pathologies (Zhao et al, 2013; McKim et al, 2016). Under normal conditions, microglia 
is found in a surveillance state as indicated by a ramified morphology with small soma. 
However, in response to a pathological stimulus, microglia morphology shifts to a 
reactive state characterized by retracted ramifications and larger amoeboid soma 
(Kohman and Rhodes, 2013). To evaluate the presence of neuroinflammation during 
nicotine withdrawal, we analyzed possible changes in microglia morphology 4 days after 
the precipitation of withdrawal. A significant increase in the perimeter of microglia soma 
was observed in nicotine abstinent mice in the stratum pyramidale (p<0.01) and stratum 
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radiatum (p<0.05) of the CA1 region of the hippocampus (Fig. 1D), and in the granular 
cell layer (p<0.01) and hilus (p<0.01) of hippocampal dentate gyrus (Fig. 1E). This effect 
was also found in the PFC (p<0.01), whereas microglial reactivity remained unaltered in 
the dorsal striatum (Fig. 1F). Moreover, chronic nicotine treatment did not modify 
microglia morphology in the CA1 region of the hippocampus (stratum pyramidale and 
stratum radiatum) and hippocampal dentate gyrus (granular cell layer and hilus) (Fig. S1), 
suggesting that microglial activation was due specifically to the withdrawal syndrome. 
These results reveal that nicotine withdrawal involves changes in microglial reactivity 
which are associated with the presence of cognitive deficits. Indeed, a significant negative 
correlation between microglial activation (soma perimeter) and memory performance 
(discrimination index) was found in the granular cell layer (Fig. 1G) and hilus (Fig. 1H) 
of the hippocampal dentate gyrus, and the PFC (Fig. 1I) in control and nicotine-withdrawn 
mice. A clear tendency (p=0.07) was also observed in the stratum pyramidale of the CA1 
region of the hippocampus (Fig. S2A).  
We next investigated hippocampal neurogenesis in the subgranular zone (SGZ) of the 
dentate gyrus, since an inflammatory environment may alter this neurobiological process 
(Kohman and Rhodes, 2013). Moreover, adult neurogenesis has a role in cognition, 
learning and memory (Yau et al, 2015). A significant decrease of the endogenous cell 
proliferation marker Ki67 was observed in nicotine-treated mice 4 days after withdrawal 
precipitation (p<0.05) (Fig. 1J and L). Immunoreactivity for the early neuron marker 
DCX was also significantly lower in nicotine-treated group (p<0.05) (Fig. 1K and L) in 
comparison with control mice. Overall, our results indicate that enhanced microglial 





3.2. Cannabidiol prevents the cognitive deficits associated with nicotine withdrawal 
through modulation of microglial reactivity 
As previously described, cognitive deficits of nicotine withdrawal course with an 
inflammatory phenotype of microglia. We next studied the effect of cannabidiol, a non-
psychoactive cannabinoid with anti-inflammatory properties (Burstein, 2015), in the 
memory impairment and microglial reactivity during nicotine withdrawal (Fig. 2A). 
Subchronic treatment with cannabidiol was administered at the doses of 3, 10 and 30 
mg/kg (once daily during 4 days) (Fig. 2A). Cannabidiol prevented the memory 
impairment of the nicotine withdrawal syndrome at the doses of 10 and 30 mg/kg in the 
object recognition test, while this compound was ineffective at the dose of 3 mg/kg (Fig. 
2B). Thus, two-way ANOVA showed an interaction between cannabidiol and nicotine 
(F3,60=4.96, p<0.05). Post hoc analysis revealed the improvement of memory induced by 
the doses of 10 and 30mg/kg (p<0.01) of cannabidiol. Total exploration time was not 
modified in these experiments (Fig. 2C).  
We next evaluated whether the improvement of cannabidiol on memory processing 
during nicotine abstinence could be due to the modulation of microglia reactivity. For this 
purpose, we used the lowest effective dose of cannabidiol (10 mg/kg). Four days after 
withdrawal precipitation, subchronic treatment with cannabidiol reduced microglial 
active phenotype in the CA1 field and the dentate gyrus of the hippocampus, and in the 
PFC. Thus, the enhanced perimeter of microglia soma observed during nicotine 
withdrawal was reversed in mice treated with cannabidiol in the stratum pyramidale 
(p<0.01) and in the stratum radiatum (p<0.01) (cannabidiol x nicotine interaction: 
F1,16=4.89, p<0.05 and F1,16=7.56, p<0.05, respectively) (Fig. 2D, E and F). Cannabidiol 
also prevented microglial activation in the granular cell layer (p<0.01) and in the hilus 
(p<0.01) of the hippocampal dentate gyrus (Fig. 2 G and H) (nicotine effect: F1,16=23.76, 
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p<0.001, cannabidiol effect: F1,16=18.52, p<0.001 and nicotine effect: F1,16=15.32, 
p<0.001, cannabidiol effect: F1,16=29.29, p<0.001, respectively), although no significant 
interactions were found in these areas. The same effect was observed in the PFC (p<0.01), 
as shown by two-way ANOVA (nicotine x cannabidiol interaction F1,12=20.00, p<0.001) 
(Fig. 2I). These results suggest that cannabidiol prevents memory deficits during nicotine 
abstinence through the modulation of microglia reactivity in key brain regions related to 
cognitive processes.  
In an additional experiment, we investigated whether cannabidiol could affect the severity 
of nicotine physical dependence (Fig. S3A). For this purpose, acute cannabidiol injection 
(10 mg/kg) was administered immediately after the training session, 20 minutes before 
the precipitation of nicotine withdrawal with mecamylamine. Somatic signs of nicotine 
withdrawal were evaluated during 25 minutes after withdrawal precipitation (Fig. S3A). 
The severity of nicotine abstinence (nicotine effect, F1,33 =32.84, p<0.01) was not 
significantly altered in mice pretreated with cannabidiol (cannabidiol x nicotine 
interaction: F1,33=4.56, NS) (Fig. S3D). Individual signs of withdrawal are shown in 
Supplemental Table S2. In contrast, similar cannabidiol treatment prevented the cognitive 
deficits observed 24 hours after nicotine withdrawal precipitation in the object-
recognition test, as shown by two-way ANOVA (cannabidiol x nicotine interaction: 
F1,30=13.84, p<0.01) and post hoc analysis (p<0.01) (Fig. S3B). Total exploration time 
was not modified in this experiment (Fig. S3C). These data suggest that different 
neurobiological mechanisms seem to be involved in the somatic signs and cognitive 





3.3. Expression of inflammatory markers is enhanced during nicotine withdrawal 
Reactive microglia has been described as a sustained source of inflammatory molecules 
(Kohman and Rhodes, 2013), which have been directly implicated in hippocampus-
dependent learning and memory (Blank and Prinz, 2013). Therefore, we studied the 
expression of some inflammatory cytokines 4 days after nicotine withdrawal precipitation 
and its regulation by cannabidiol subchronic treatment (10mg/kg, once daily during 4 
days) in the hippocampus and the PFC. Quantitative analysis of the mRNA of 
inflammatory markers in hippocampal homogenates showed an enhanced expression of 
IL1β, TNFα, IL10 and IFNγ (Fig. 3A). Two-way ANOVA analysis showed a significant 
effect of nicotine treatment in the expression of TNFα (F1,23=10.57, p<0.01) and IL10 
(F1,23=17.30, p<0.001). Two-way ANOVA also revealed a significant interaction between 
nicotine and cannabidiol treatment in the mRNA levels of IL1β (F1,23=9.65, p<0.01) and 
IFNγ (F1,23=5.77, p<0.05). Interestingly, post hoc analysis showed a normalization of the 
expression of IL1β (p<0.05) by cannabidiol, while this compound did not affect the 
increase of IFNγ induced by nicotine abstinence (p=0.32) (Fig. 3A). Neither nicotine 
abstinence nor cannabidiol administration altered the expression of COX1, COX2, IL6 
and BDNF in the hippocampus (Fig. S4). Similarly to the effects observed in the 
hippocampus, nicotine withdrawal increased the expression of IL1β (nicotine treatment: 
F1,26=9.76, p<0.01), and IFNγ (nicotine treatment: F1,26=6.84, p<0.05) in the PFC (Fig. 
3B). No effect was found in IL10 mRNA levels (nicotine treatment: F1,25=0.06, NS). Two-
way ANOVA also revealed a significant interaction between nicotine and cannabidiol 
treatment in the expression of TNFα (F1,26=7.35, p<0.01). Cannabidiol reversed the 
increase of this cytokine induced by nicotine withdrawal, as indicated by post hoc analysis 
(p<0.05) (Fig. 3B). In contrast to the result obtained in the hippocampus, cannabidiol did 
not alter IL1β expression in the PFC (Fig. 3B). These results suggest that cannabidiol 
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could improve memory performance during nicotine abstinence normalizing the 
expression of IL1β and TNFα in the hippocampus and the PFC, respectively. However,   
since alterations in mRNA levels do not necessarily translate into changes in synthesis 
and release of cytokines, the evaluation of protein levels of these cytokines in the 
hippocampus and PFC will require special attention in future experiments.   
We next investigated the role of peripheral pro-inflammatory cytokines as potential 
biomarkers of the cognitive deficits associated with early nicotine abstinence, given the 
increased expression of several of these molecules in the hippocampus and the PFC. 
Notably, flow cytometric analysis revealed a significant increase of plasmatic levels of 
TNFα (p<0.05) and IFNγ (p<0.01), but not IL10, 4 days after the precipitation of nicotine 
withdrawal (Fig. 3C). Under similar experimental conditions, mice completely recovered 
from cognitive impairment 8 days after abstinence precipitation (Saravia et al, 2017). 
Interestingly, differences in cytokine plasmatic levels were not observed at this time point 
(Fig. S5), suggesting that cognitive deficits of nicotine withdrawal are associated with an 
enhancement of peripheral inflammatory cytokines.  
 
3.4. Effects of cannabidiol on neurogenesis during nicotine withdrawal 
As previously described, cognitive deficits of nicotine withdrawal are associated with 
impaired neurogenesis in the SGZ of the hippocampal dentate gyrus. To evaluate the 
effect of cannabidiol on neurogenesis, mice underwent a subchronic cannabidiol 
treatment (10mg/kg, once daily during 4 days). Interestingly, cannabidiol showed a clear 
tendency to increase Ki67+ cells 4 days following nicotine abstinence precipitation as 
shown by two-way ANOVA (nicotine x cannabidiol interaction: F1,20=10.07, p<0.01) and 
subsequent post hoc analysis (p=0.06) (Fig. 4A and B). Regarding DCX 
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immunoreactivity, cannabidiol did not modify (p=0.20) the expression of this marker of 
young neurons in spite of a significant interaction between nicotine and cannabidiol 
treatment (F1,20=6.60, p<0.05) (Fig. 4C). These results indicate that the improvement of 
cognitive function induced by cannabidiol administration may involve a promotion of cell 
proliferation in the hippocampus.   
 
3.5. The nonsteroidal anti-inflammatory drug indomethacin counteracts cognitive 
deficits and microglia reactivity associated with nicotine withdrawal 
We next evaluated the effects of indomethacin, a NSAID, on the cognitive impairment 
associated with nicotine abstinence. This study was based on the fact that modulation of 
the pro-inflammatory phenotype seems to be a key element to prevent withdrawal-related 
cognitive deficits. Interestingly, subchronic treatment with indomethacin (2mg/kg, once 
daily during 4 days) reversed memory deficiency 4 days following precipitation of 
nicotine abstinence, as revealed by two-way ANOVA (nicotine x indomethacin 
interaction: F1,45=4.95, p<0.05), and post hoc analysis (p<0.01) (Fig. 5A). Total time of 
exploration was similar in the different experimental groups (Fig. 5B). Indomethacin 
treatment ameliorated the effects of nicotine withdrawal on microglial reactivity. Thus, 
two-way ANOVA revealed a significant interaction between nicotine and indomethacin 
in the stratum pyramidale (F1,12=9.19, p<0.01) and the stratum radiatum (F1,12=6.70, 
p<0.05) of the CA1 hippocampal region. Subsequent post hoc analysis showed that 
pretreatment with indomethacin reduced microglial soma perimeter in nicotine abstinent 
mice in both regions (p<0.01) (Fig. 5C and D). Similarly, indomethacin reduced the 
activation of microglia in the granular cell layer (p<0.01) and hilus (p<0.05) of the 
hippocampal dentate gyrus, as shown by two-way ANOVA (nicotine x indomethacin 
interaction: F1,12=8.04, p<0.05 and F1,12=5.88, p<0.05, respectively). These data suggest 
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that the modulation of inflammation is a potential novel target for alleviating cognitive 




Our results identify new mechanisms involved in the cognitive deficits associated with 
nicotine abstinence and support novel possible therapeutic strategies. Microglial 
activation and increased expression of pro-inflammatory cytokines were found in the 
hippocampus and the PFC 4 days after nicotine withdrawal in male mice, when the 
cognitive deficits are still present. Impaired neurogenesis was also observed in the SGZ 
of the dentate gyrus in the hippocampus during nicotine withdrawal. Notably, cannabidiol 
and indomethacin prevented memory impairment of nicotine withdrawal and most of 
these neurobiological alterations. These data suggest the usefulness of anti-inflammatory 
agents to normalize cognition during early abstinence, which could have a therapeutic 
interest since these cognitive deficits are related to increased risk of relapse to tobacco 
consumption in humans.  
Around 50% to 75% of smokers relapse during the first week of a quit attempt (Ashare et 
al, 2014). Increasing attention has focused on cognitive impairments that emerge during 
smoking abstinence given that these deficits may predict relapse (Patterson et al, 2010; 
Loughead et al, 2015). FDA-approved medications, such as varenicline and bupropion, 
can reverse abstinence-induced working memory deficits as revealed in abstinent smokers 
tested during medication in comparison with placebo (Loughead et al, 2010; Perkins et 
al, 2013). Although the mechanisms that mediate nicotine withdrawal-induced cognitive 
impairments are not clear, different studies have suggested a role for CB1 cannabinoid 
receptors (Evans et al, 2016; Saravia et al, 2017), neuropeptide CART (Borkar et al, 
2017), α4β2 nicotinic acetylcholine receptors (Yildirim et al, 2015) or noradrenaline 
(Davis and Gould, 2007) in these deficits.   
The precipitation of nicotine withdrawal with mecamylamine after the training phase 
revealed a memory consolidation impairment in the object-recognition task, which was 
present at least during 4 days, as previously reported (Saravia et al, 2017). In agreement, 
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several studies have shown similar cognitive deficits in other hippocampal-dependent 
tasks in rodents such as the spatial object-recognition and contextual fear conditioning 
during spontaneous (Wilkinson et al, 2013; Yildirim et al, 2015) and precipitated nicotine 
withdrawal (Raybuck and Gould, 2009). Under similar experimental conditions, chronic 
nicotine exposure did not modify memory performance (Saravia et al, 2017) suggesting 
that the cognitive deficits observed were specific of the withdrawal period. In agreement, 
chronic nicotine administration does not affect memory performance in rodents (Raybuck 
and Gould, 2009; Davis et al, 2005).   
Microglia cells play crucial roles in normal development, plasticity and maintenance of 
neural circuits (Wake et al, 2013). Under conditions of disturbed brain homeostasis, 
microglia structure and function are rapidly altered. Although morphological and 
functional changes are essential for coping with pathogenic challenges (Yirmiya et al, 
2015), these changes can also compromise and interfere with the normal brain 
physiological function (Wake et al, 2013). Memory impairment during nicotine 
withdrawal was associated with microglial activation in key brain regions regulating 
cognitive processes. Thus, amoeboid morphology characterized by an enlargement of the 
soma perimeter was found in the CA1 field and dentate gyrus of the hippocampus, and in 
the PFC. This alteration was not observed in other brain areas such as the dorsal striatum. 
The stressful condition occurring during nicotine withdrawal could be responsible for this 
microglial activation since ample evidence demonstrates how stress exposure can induce 
changes in microglia structure and function leading to cognitive deficits (Yirmiya et al, 
2015; Tay et al, 2017). Activation of microglia in the PFC and hippocampus has been 
related to the cognitive impairments that characterize stress-related conditions (Hinwood 
et al, 2013; McKim et al, 2016). Corticotropin-releasing factor is involved in the 
dysphoria and anxiety-like behavior observed during nicotine withdrawal (Bruijnzeel, 
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2017), while blockade of corticosterone effects abolishes acute or chronic stress-induced 
microglial proliferation and activation (Frank et al, 2012; de Pablos et al, 2014). 
Congruent with microglial activation, we found an increased mRNA expression of several 
inflammatory markers such as IL1β, TNFα, and IFNγ in both the hippocampus and the 
PFC during nicotine withdrawal. Overexpression of pro-inflammatory cytokines in the 
CNS has been associated with several neuropsychiatric disorders including depression, 
Alzheimer’s disease and Parkinson’s disease (Borsini et al, 2015). Notably, an elevation 
of plasmatic levels of TNFα and IFNγ was also observed 4 days after nicotine withdrawal 
precipitation suggesting that these cytokines could be investigated as biomarkers of the 
cognitive deficits present during tobacco abstinence. Indeed, cytokine levels in plasma 
were normalized by the 8th day of withdrawal when mice are recovered from memory 
impairment under our experimental conditions (Saravia et al, 2017). Inflammatory 
cytokines including IL1β, TNFα, and IFNγ are also key modulators of neurogenesis 
(Borsini et al, 2015), which has a critical role in mediating human brain functions 
including memory formation and cognition (Kohman and Rhodes, 2013). Interestingly, 
cognitive deficits of nicotine withdrawal were associated with reduced expression of cell 
proliferation and young neuron markers in the SGZ of the hippocampus. Taken together, 
these results suggest that inflammation-induced deficits in cognitive performance during 
nicotine withdrawal could be related to the reductions in hippocampal neurogenesis. 
A dramatic increase in the interest of the non-psychoactive cannabinoid cannabidiol has 
been revealed in recent years. This compound has anti-inflammatory and neuroprotective 
properties (Fernández-Ruiz et al, 2013; Burstein, 2015), with potential benefits for the 
treatment of motivational disorders such as drug addiction, anxiety and depression 
(Zlebnik and Cheer, 2016). Subchronic treatment with cannabidiol prevented the memory 
impairment in the object-recognition task and the activation of microglia in the 
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hippocampus and the PFC observed 4 days after nicotine withdrawal. In agreement, 
cannabidiol has been shown to improve object-recognition memory in preclinical models 
that course with cognitive impairment, including schizophrenia (Gomes et al, 2015), 
Alzheimer’s disease (Cheng et al, 2014), brain ischemia (Pazos et al, 2012) and cerebral 
malaria (Campos et al, 2015). Cannabidiol also normalized the increased expression of 
IL1β and TNFα in the hippocampus and the PFC, respectively, observed during nicotine 
withdrawal. Although present data about possible regulation of neuroinflammatory 
markers by cannabidiol in preclinical models of cognitive impairment are sparse and 
controversial (Osborne et al, 2017), some studies suggest a possible involvement of TNFα 
in the mechanisms underlying the ability of cannabidiol to improve cognition (Osborne 
et al, 2017). In addition, cannabidiol treatment tended to promote cell proliferation during 
nicotine withdrawal in the SGZ of the hippocampal dentate gyrus. Accordingly, an 
increase of hippocampal neurogenesis following cannabidiol administration was 
observed in a rat model of Alzheimer’s disease (Esposito et al, 2011). As a whole, these 
data indicate that cannabidiol might improve cognitive performance during nicotine 
withdrawal through the modulation of inflammation and cell proliferation. Interestingly, 
preliminary findings in humans show that cannabidiol reduces cigarette consumption 
(Morgan et al, 2013), and pleasantness of cigarette cues after overnight abstinence 
(Hindocha et al, 2018a) in tobacco smokers. In contrast, a recent study has shown that 
acute administration of a single dose of cannabidiol did not improve memory performance 
in tasks previously shown to be impaired during cigarette abstinence (Hindocha et al, 
2018b). The effects of repeated administration of different doses of cannabidiol on 
cognition should be evaluated in dependent smokers (Hindocha et al, 2018b), considering 
the bell-shaped dose response effects widely reported for this compound and higher 
effectiveness usually revealed after repeated administration (Zuardi et al, 2017).     
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We next investigated the effects of the NSAID indomethacin in order to verify whether 
the improvement of memory performance by cannabidiol could be generalized to other 
anti-inflammatory agents. Therefore, although interesting, no direct comparison between 
the effects of cannabidiol and indomethacin was made. Notably, indomethacin 
administration rescued memory impairment during nicotine withdrawal and prevented 
concurrent microglial activation in the CA1 field and dentate gyrus of the hippocampus. 
Congruent with this observation, indomethacin abolished recognition memory deficits 
reveal during intermittent ethanol intoxication (Pascual et al, 2007), and in a mouse model 
of Alzheimer's disease (Balducci et al, 2017), but not in a model of social defeat stress 
(Duque et al, 2017). Indomethacin is a broad spectrum NSAID that inhibits 
cyclooxigenase (Cox)-1 and -2 activity, although hippocampal mRNA expression of Cox-
1 and -2 was not modified under our experimental conditions.  
The use only of male mice is a limitation of this study since several reports show 
evidences for sex differences in the central effects of nicotine in rodent models (Flores et 
al, 2017; Peartree et al, 2017). Although social factors are crucial in smoking dependence 
in humans, differences in the pharmacokinetic properties of nicotine or the effect of 
gonadal hormones may underlie some of the sex differences observed (Pogun and 
Yararbas, 2009). Moreover, recent studies show that sex could modulate the effects of 
tobacco smoke on inflammation (Ashare and Wetherill, 2018). A pilot study in humans 
also suggested the presence of cognitive differences between sexes during tobacco 
abstinence (Merrit et al, 2012). Therefore, the investigation about how males and females 
might differ in the effects of tobacco abstinence on memory and cognition will require 
special attention in the future. On the other hand, the evaluation of the neurobiological 
mechanisms described here under spontaneous nicotine withdrawal would be also 
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interesting since these experimental approach might add translational value to the results 
obtained in our study.  
In summary, our work reveals for the first time an inflammatory process associated with 
the cognitive deficits that characterize early nicotine abstinence. Moreover, these findings 
underline the efficacy of anti-inflammatory agents to improve cognitive deficits during 
nicotine withdrawal. Given that the presence of cognitive alterations are associated with 
increased smoking relapse risk, our results identify anti-inflammatory drugs as new 
potential therapeutic strategies for nicotine dependence.                                
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Figure 1  
Microglial activation and impaired neurogenesis are associated with the cognitive deficits 
during nicotine withdrawal. (A) Schematic representation of the experimental design for 
(B-C) behavioral procedures. Memory and perimeter of microglia soma were evaluated 
4 days after the precipitation of nicotine withdrawal by mecamylamine administration 
(2mg/kg). (B) Discrimination index and (C) total exploration time obtained in the novel 
object-recognition paradigm (n = 7 mice per group). (D-F) Perimeter of microglia soma 
in the (D) stratum pyramidale and stratum radiatum of the CA1 region of the 
hippocampus, the (E) granular cell layer and hilus of the hippocampal dentate gyrus, the 
(F) dorsal striatum and the prefrontal cortex (n = 4-7 mice per group). (D-F) 
Representative images of microglial cells obtained via confocal microscopy after direct 
labeling with rabbit polyclonal antiserum to Iba-1 in nicotine abstinent and control mice. 
Scale bar represents 20µm. (G-I) Correlation between memory performance 
(discrimination index values) and microglial activation (soma perimeter values) in the 
(G) granular cell layer and the (H) hilus of the hippocampal dentate gyrus, and (I) 
prefrontal cortex. (J-L) Neurogenesis in the SGZ of the hippocampus assessed by the (J) 
density of Ki67+ cells (n = 5-6 mice per group) and the (K) percentage of control 
doublecortin (DCX) immunoreactivity integrated density (n = 6 mice per group). (L) 
Representative images of both Ki67 and DCX markers in nicotine abstinent and control 
mice. Scale bar represents 100µm. Data are expressed as mean ± SEM. p<0.05, 
p<0.01 compared with the saline group. DG, dentate gyrus; SGZ, subgranular zone; 






Cannabidiol prevents the cognitive deficits of nicotine abstinence through the modulation 
of microglial reactivity. (A) Schematic representation of the experimental design for (B-
C) behavioral procedures to evaluate the effects of  subchronic treatment with cannabidiol 
on memory impairment during nicotine withdrawal. (B-C) Cannabidiol was administered 
immediately after the training session 20 minutes before the precipitation of nicotine 
withdrawal. Cannabidiol (3, 10 and 30mg/kg) was injected once daily during 4 days and 
discrimination index (B) and total exploration time (C) was obtained 4 days after the 
training (n = 8-10 mice per group).  (E-J) Soma perimeter of microglial cells in the (E) 
stratum pyramidale and (F) stratum radiatum of the CA1 region of the hippocampus, the 
(H) granular cell layer and (I) hilus of the hippocampal dentate gyrus, and (J) prefrontal 
cortex (n = 4-5 mice per group) (G) Representative images of microglial cells from the 
CA1 area of the hippocampus obtained via confocal microscopy after direct labeling with 
rabbit polyclonal antiserum to Iba-1. Scale bar represents 20µm. Data are expressed as 
mean ± SEM. p < 0.01 compared with the saline-treated groups in (B); p < 0.01 
compared with the saline-vehicle group, ##p < 0.01 compared with the nicotine-vehicle 




Cannabidiol modulates the expression of neuroinflammatory markers during nicotine 
withdrawal. (A-B) Expression of inflammatory markers IL1b, TNFα, IL10 and IFNγ in 
homogenates of (A) hippocampus and (B) prefrontal cortex of nicotine abstinent and 
control mice 4 days after the precipitation of nicotine withdrawal. Mice were treated with 
cannabidiol (10mg/kg, once daily during 4 days) or vehicle (n = 6-9 mice per group). (C) 
39 
 
Plasmatic levels of TNFα, IL10 and IFNγ in nicotine abstinent or control mice 4 days 
after the precipitation of withdrawal (n = 9 mice per group). Data are expressed as mean 
± SEM. p < 0.05, p < 0.01 compared with the saline group; #p < 0.05 compared with 
the nicotine-vehicle group. HPC, hippocampus; PFC, prefrontal cortex. 
 
Figure 4  
Cannabidiol promotes hippocampal cell proliferation during nicotine withdrawal. (A) 
Density of the endogenous cell proliferation marker Ki67 and (C) Percentage of control 
DCX immunoreactivity expressed as integrated density in the SGZ of the dentate gyrus 
(n = 6 mice per group) 4 days after nicotine withdrawal precipitation in mice treated with 
vehicle or cannabidiol (10mg/kg, once daily during 4 days). (B) Representative images 
of Ki67 labeling in the SGZ of the dentate gyrus. Arrows indicate Ki67+ cells. Scale bar 
represents 100µm. Data are expressed as mean ± SEM. p < 0.05, compared with the 
saline-vehicle group. DG, dentate gyrus; SGZ, subgranular zone; DCX, doublecortin.  
 
Figure 5 
Nonsteroidal anti-inflammatory drug (NSAID) indomethacin abolishes the cognitive 
deficits associated with nicotine withdrawal. Memory was evaluated 4 days after nicotine 
withdrawal precipitation in mice treated with indomethacin (2mg/kg, once daily during 4 
days) or vehicle. (A) Discrimination index and (B) total exploration time obtained in the 
novel object-recognition paradigm (n = 12-14 mice per group). (C-G) Soma perimeter of 
microglial cells of the (C) stratum pyramidale and (D) stratum radiatum of the CA1 
hippocampal area, and (F) granular cell layer and (G) hilus of the hippocampal dentate 
gyrus (n = 4 mice per group). (E) Representative images of microglial cells from the CA1 
area obtained via confocal microscopy after direct labeling with rabbit polyclonal 
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antiserum to Iba-1. Scale bar represents 20µm. Data are expressed as mean ± SEM. p < 
0.05, p < 0.01 compared with the saline-vehicle group; ##p < 0.01 compared with the 
nicotine-vehicle group.  
 
 
